Biotechnology

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 17, 2021 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to receive $10 million upfront payment and is eligible to receive up to...

Read more

Applied UV Reports First Quarter 2021 Results

May 17, 2021 7:00 AM

MOUNT VERNON, NY / ACCESSWIRE / May 17, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced first quarter results for 2021. Q Saeed, Chief Executive Officer, commented,...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results

May 14, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an update on its business. The company reported that it has enrolled more than 285 patients in an ongoing Phase 2/3 clinical study of its investigational drug, EB05, as a...

Read more

Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 13, 2021 4:00 PM

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial  Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeutics Goal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccines Engaged CR2O...

Read more

Pressure BioSciences Awarded Three Additional Patents for Revolutionary Ultra Shear Technology Platform

May 13, 2021 10:10 AM

Unique Commercial-Scale Capabilities for Highest-Quality Nanoemulsions of Oils in Water Enabled by PBI's UST Platform, Addressing Multiple Billion Dollar Opportunities in Diverse Markets Worldwide SOUTH EASTON, MA / ACCESSWIRE / May 13, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the...

Read more

Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

May 13, 2021 9:00 AM

RICHMOND HILL, ON / ACCESSWIRE / May 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based...

Read more

Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange

May 12, 2021 10:10 PM

SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange. The Company, its Board, advisors and management team are going to devote resources to accomplish this as swiftly as possible. We are delighted to have...

Read more

Apollo Endosurgery to Present at Sidoti Conference May 20

May 12, 2021 4:05 PM

AUSTIN, TX / ACCESSWIRE / May 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the Sidoti & Company Virtual Microcap Conference on May 20, 2021. Management will present an overview presentation on Thursday, May 20, at 10:00 am Eastern Standard Time. A live and archive webcast link to the group...

Read more

BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time

May 12, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / May 12, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public. The webcast and conference call will be held to review the company's financial results, discuss recent company developments, and conduct a...

Read more

Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

May 12, 2021 7:05 AM

New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India. The patent is...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

May 12, 2021 7:00 AM

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE / May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...

Read more

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021 4:01 PM

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk...

Read more

Havn Life Develops New Method for Rapid Psilocybin Testing

May 11, 2021 8:00 AM

Havn Life has completed its analytical work under its Health Canada Section 56 exemption VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / Havn Life Sciences Inc. (CSE:HAVN) (OTC PINK:HAVLF) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has completed the analytical work under its Health...

Read more

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

May 11, 2021 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / May 11, 2021 / Helix BioPharma Corp.(TSX:HBP)("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC...

Read more

AngioSoma, Inc. Is Pleased To Welcome Darryl Morris As A Strategic Economic Advisor

May 11, 2021 7:19 AM

Morris' economic, strategic, and market intellingence experience will play a key role in the growth of AngioSoma. RICHLAND, WA / ACCESSWIRE / May 11, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has added Darryl Morris as a Strategic Economic Advisor. Morris has over three decades of economic, strategic, and market intelligence experience working with companies, such as Abbott Laboratories. Headquartered in Richland, Washington, AngioSoma, Inc....

Read more

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

May 11, 2021 6:30 AM

First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the acceleration of a revolutionary Phase 2...

Read more

Applied UV to Host Q1 2021 Conference Call on May 17th

May 10, 2021 11:45 AM

MOUNT VERNON, NY / ACCESSWIRE / May 10, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will host an investor conference call and live webcast to discuss...

Read more

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

May 10, 2021 8:30 AM

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will...

Read more

Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021

May 10, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2021 investor call on Monday, May 17, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access...

Read more

Liviana Artisanal CBD Olive Oils Have Arrived

May 7, 2021 9:05 AM

CAPE TOWN, SA / ACCESSWIRE / May 7, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The Liviana CBD Infused Extra Virgin Olive Oils first batch is ready to hit the shelves. The premium product range consists of: Estate Select Extra Virgin Olive Oil...

Read more